AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
DiscussionA safe, sustainable and easy to administer regimen of L-AmB that is non-inferior to seven days of daily amphotericin B deoxycholate therapy may reduce the number of adverse events seen in patients treated with amphotericin B deoxycholate and shorten hospital admissions, providing a highly favourable and implementable alternative to the current WHO recommended first-line treatment.Trial registrationISRCTN,ISRCTN72509687. Registered on 13 July 2017. (Source: Trials)
Source: Trials - November 23, 2018 Category: Research Source Type: clinical trials
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
Condition: Visceral Leishmaniasis Interventions: Drug: Amphotericin B Liposome; Drug: AmBisome (Amphotericin B) Liposome Sponsors: Aurobindo Pharma Ltd; Axis Clinicals Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 17, 2018 Category: Research Source Type: clinical trials
